NASDAQ · SYRE
Spyre Therapeutics, Inc.
$98.96-$0.79 (-0.79%)
Spyre Therapeutics, Inc.’s quoted price sits in the upper half of its reported 52-week range, 10.18% below the high.
Loading market information…
NASDAQ · KNSA · USD
Stock price, earnings
Quote as of Oct 29, 2026, 08:00 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
Kiniksa Pharmaceuticals International, plc’s quoted price sits in the upper half of its reported 52-week range, 0.81% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Kiniksa Pharmaceuticals International, plc’s next earnings report is currently expected on Feb 23, 2027, with estimated earnings per share of $0.25. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow Kiniksa Pharmaceuticals International, plc’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Kiniksa Pharmaceuticals International, plc, a biopharmaceutical company, develops and commercializes medical therapies in the United States, the United Kingdom, and internationally. The company offers ARCALYST, an interleukin-1alpha and 1beta cytokine trap for the treatment of recurrent pericarditis, a chronic autoinflammatory cardiovascular disease and cardiac sarcoidosis. It also develops KPL-387, an investigational and fully human immunoglobulin G2 monoclonal antibody, which is Phase 2/3 clinical trial for the treatment of recurrent pericarditis; and KPL-116, a Fc-modified immunoglobulin G2 monoclonal antibody, which is in pre-clinical stage. The company was formerly known as Kiniksa Pharmaceuticals, Ltd. and changed its name to Kiniksa Pharmaceuticals International, plc in June 2024. Kiniksa Pharmaceuticals International, plc was incorporated in 2015 and is based in London, the United Kingdom.
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 05:43 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
| $180.86M-8.24% vs estimate |
| Q2 2025 | Jul 29, 2025 | $0.23+27.78% vs estimate | $156.80M-5.82% vs estimate |
|---|
| Q1 2025 | Apr 29, 2025 | $0.11+450.0% vs estimate | $137.79M+4.48% vs estimate |
|---|
| Q4 2024 | Feb 25, 2025 | -$0.12-100.0% vs estimate | $122.54M-0.71% vs estimate |
|---|
THE ANALYST VIEW
11 ratings in the current snapshot. Strong buy and strong sell are grouped with buy and sell.
Percentages compare targets with the quoted price when currencies match. Targets are analyst estimates, not guaranteed outcomes.
Consensus coverage: 4 contributors · Median target $98.50.
Average targets in published notes for each window. These figures use a different sample from the consensus above.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
$98.96-$0.79 (-0.79%)
Spyre Therapeutics, Inc.’s quoted price sits in the upper half of its reported 52-week range, 10.18% below the high.
$96.65+$0.68 (+0.71%)
Oruka Therapeutics, Inc.’s quoted price sits in the upper half of its reported 52-week range, 16.33% below the high.
$29.64+$0.22 (+0.75%)
Immunovant, Inc.’s quoted price sits in the lower half of its reported 52-week range, 34.74% below the high.
$82.70+$0.39 (+0.47%)
Dianthus Therapeutics, Inc.’s quoted price sits in the upper half of its reported 52-week range, 29.84% below the high.
$27.12-$0.14 (-0.51%)
Nurix Therapeutics, Inc.’s quoted price sits in the upper half of its reported 52-week range, 3.93% below the high.
$48.64-$1.86 (-3.68%)
AnaptysBio, Inc.’s quoted price sits in the upper half of its reported 52-week range, 32.78% below the high.
$12.13-$0.13 (-1.06%)
Pharming Group N.V.’s quoted price sits in the lower half of its reported 52-week range, 43.16% below the high.
$3.99+$0.03 (+0.76%)
Aclaris Therapeutics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 39.55% below the high.
